title: Effect of niacin therapy on cardiovascular outcomes in patients with coronary artery disease.
abstract: BACKGROUND
  Niacin or nicotinic acid (vitamin B3) raises the levels of high-density lipoprotein cholesterol (HDL) by about 30% to 35%. In patients with prior coronary disease, 7 trials have been published on clinical cardiovascular disease outcomes and the results, not surprisingly, are inconsistent. Hence, we performed this meta-analysis of randomized placebo-controlled trials (RCTs) to evaluate the effect of niacin on cardiovascular outcomes in patients with coronary artery disease.
  
  
  METHODS
  A systematic search using PubMed, EMBASE, and Cochrane library databases was performed. Seven studies with a total of 5137 patients met our inclusion criteria. Heterogeneity of the studies was analyzed by the Cochran Q statistics. The significance of common treatment effect was assessed by computing the combined relative risks using the Mantel-Haenszel fixed-effect model. A 2-sided alpha error of less than .05 was considered statistically significant (P < .05).
  
  
  RESULTS
  Compared to placebo group, niacin therapy significantly reduced coronary artery revascularization (RR [relative risk]: 0.307 with 95% CI: 0.150-0.628; P = .001), nonfatal myocardial infarction ([MI]; RR: 0.719; 95% CI: 0.603-0.856; P = .000), stroke, and TIA ([transient ischemic attack] RR: 0.759; 95%CI: 0.613-0.940; P = .012), as well as a possible but nonsignificant decrease in cardiac mortality (RR: 0.883: 95% CI: 0.773-1.008; p= 0.066).
  
  
  CONCLUSIONS
  In a meta-analysis of seven trials of secondary prevention, niacin was associated with a significant reduction in cardiovascular events and possible small but non-significant decreases in coronary and cardiovascular mortality.
authors.affiliation: Chicago Medical School and Affiliated Hospitals, Rosalind Franklin University of Medicine & Science, North Chicago, IL, USA.
authors.forename: Jasleen K
authors.initials: JK
authors.lastname: Duggal
authors.forename: Mukesh
authors.initials: M
authors.lastname: Singh
authors.forename: Navneet
authors.initials: N
authors.lastname: Attri
authors.forename: Param P
authors.initials: PP
authors.lastname: Singh
authors.forename: Neyaz
authors.initials: N
authors.lastname: Ahmed
authors.forename: Suneet
authors.initials: S
authors.lastname: Pahwa
authors.forename: Janos
authors.initials: J
authors.lastname: Molnar
authors.forename: Sarabjeet
authors.initials: S
authors.lastname: Singh
authors.forename: Sandeep
authors.initials: S
authors.lastname: Khosla
authors.forename: Rohit
authors.initials: R
authors.lastname: Arora
mesh_terms: D002318:Cardiovascular Diseases / Q000401:mortality / Q000517:prevention & control; D003324:Coronary Artery Disease / Q000188:drug therapy* / Q000401:mortality / Q000517:prevention & control; D006801:Humans; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D009203:Myocardial Infarction / Q000401:mortality / Q000517:prevention & control; D009204:Myocardial Revascularization / Q000706:statistics & numerical data; D009525:Niacin / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic
chemical_list: D000960:Hypolipidemic Agents; D009525:Niacin